Passar para o conteúdo principal
LAKE OSWEGO, Oregon, USA
Press Release

BIOTRONIK Neuro Launches BioVantage™ Remote Care Review First-of-Its-Kind Service Expands Care with a Monthly Treatment Review to Support Spinal Cord Stimulation Patients in Achieving Optimal Relief and Long-Term Therapy Engagement

BIOTRONIK Neuro today announced an entirely new service option for Prospera™ patients, called BioVantage™. This expanded service option complements Prospera's daily remote monitoring by providing patients a remote, monthly check-in with an experienced spinal cord stimulation (SCS) specialist from BIOTRONIK Neuro’s Embrace One™ Care Team. The goal is to enhance patient therapy education and support, promoting not just optimal pain relief but also consistent progress toward the treatment plan. Ultimately, BioVantage aims to prolong patient engagement and compliance. 

Remote patient management has been used to successfully improve outcomes for patients with other chronic health conditions. Patients suffering from cardiovascular diseases have long benefited from routine, remote follow-up. BioVantage builds on BIOTRONIK’s more than 20 years of experience with remote therapy monitoring for patients implanted with pacemakers or defibrillators to apply this method of care to SCS therapy.

Every Prospera™ patient receives Proactive Care – automatic, objective, daily device monitoring that notifies BIOTRONIK Neuro’s Embrace One™ Care Team of potential therapy issues – so they can intervene before patients recognize a problem. BioVantage gives patients and their physicians the option to upgrade this service to include regular, monthly treatment plan reviews. Whether or not there is a potential therapy issue, BioVantage ensures a monthly patient check-in to confirm progress with their SCS therapy and treatment goals. These check-ins also allow patients to get answers to their device-related questions from the convenience and comfort of their own home.

Physicians can efficiently enroll patients, set therapy goals, and maintain control over treatment plans, while BIOTRONIK Neuro’s Embrace One™ Care Team handles scheduling, conducts monthly treatment plan reviews, and provides detailed reports to the physician, ensuring complete transparency. BioVantage was designed to meet payer guidelines associated with remote therapeutic monitoring codes, so physicians may seek reimbursement for time spent on treatment plan development, reviews, and overall patient management. This paid service helps make remote patient follow-up financially sustainable, expanding patient care without reducing clinic efficiency.

“With BioVantage, I feel a sense of security knowing that there is a layer of monitoring to ensure that we are meeting our treatment goals,” said Ramo Naidu, MD, Director of Pain Management at MarinHealth Medical Center and MarinHealth Spine Institute. “Without adding extra appointments for my clinic team, I know these Prospera SCS patients have the support they need to successfully manage their pain.”

BIOTRONIK Neuro continues to lead the way in innovating SCS patient management. This recent advancement aligns seamlessly with the recommendations of SCS experts1, reinforcing the potential of remote therapy monitoring to elevate patient care and mitigate the risk of therapy abandonment.

-END-

 

References:

1. Staats P., Deer T.R., Hunter C., Li S., Dickerson D., Petersen E., Kapural L., Durbhakula S., Gilligan C., Slavin K.V., Pope J., Amirdelfan K., Poree L., Naidu R., Levy R.M. 2023. Remote Management of Spinal Cord Stimulation Devices for Chronic Pain: Expert Recommendations on Best Practices for Proper Utilization and Future Considerations. Neuromodulation 2023; 26: 1295–1308.

 

Disclaimers:

Embrace One™ is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.

Proactive Care: BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.

BioVantage™ is an elective, paid subscription offering from BIOTRONIK Neuro, Inc.  All services are provided under the general supervision of a physician. BioVantage is designed to meet payer guidelines associated with remote therapeutic monitoring codes, but submission of claims for reimbursement is solely at the discretion of the supervising physician. Billing and coding information is subject to frequent and unexpected change; therefore, BIOTRONIK Neuro recommends that healthcare providers refer to the information sources to verify accuracy prior to acting on the information provided. BIOTRONIK Neuro strongly encourages providers to submit accurate and appropriate claims for services and recommends direct consultation with payers (e.g., the Centers for Medicare & Medicaid Services [CMS]), certified reimbursement coding professionals, other reimbursement experts, and/or legal counsel regarding all coding, coverage, and payment issues. BIOTRONIK Neuro makes no representation or warranty regarding the accuracy, completeness, or applicability of reimbursement information, and specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on such information.

About BIOTRONIK:

At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.